Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Trimethoprim/sulfamethoxazole (TMP/SMZ) for Eczema

Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S.

Official registry: https://clinicaltrials.gov/study/NCT01631617 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · enrollment listed as 130

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, or Doxycycline. The registry lists allocation as randomized. Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder.

They plan to enroll about 130 people at Bethesda. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis

Interventions: Trimethoprim/sulfamethoxazole (TMP/SMZ), Cephalexin, Doxycycline, Sodium hypochlorite, Placebo capsules, Placebo Sodium hypochlorite

Primary outcome (registry wording): Characterize microbiome alterations

Who it is for (from inclusion criteria)

  • Ages 2 Years to 50 Years
  • Cohorts 1 \[NO FURTHER ACCRUAL\], 2 \[INACTIVE\], 4 \[NO FURTHER ACCRUAL\] and 5 \[INACTIVE\]: Healthy Volunteers
  • Males and females aged 18-50 years at time of initial protocol sampling
  • Subjects must be co-enrolled in NIH protocol 08-HG-0059
  • Access to bathing facilities (Cohort 2 \[INACTIVE\])
  • Ability to swallow capsules or tablets
  • Cohort 3 \[INACTIVE\]: Atopic Dermatitis Patients
  • Subjects must be aged 2-50 years

Public study contact (from the registry)

Heidi H Kong, M.D.

(301) 827-2460

NIAMSderm@nih.gov

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT01631617 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT01631617?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT01631617?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary